Abstract
Objective To evaluate the influence and safety of rosuvastatin on hyperuricemia (HUA) patients with coronary atherosclerotic heart disease (CHD) in coastal areas.Methods Eighty HUA patients complicated with CHD were enrolled and divided into the rosuvastatin group with rosuvastatin 10 mg/d (n =40) and the simvastatin group with simvastatin 20 mg/d (n =40),for 12 weeks continuously.The serum levels of uric acid(UA),high sensitive C-reactive protein(hs-CRP),lipids,hepatic and renal function,creatine kinase(CK) were detected before and after treatment.Results The serum levels of UA,hs-CRP,total cholesterol(TC),low-density lipoprotein cholesterol (LDL-C),triglyceride (TG) were significantly lower after 12-week treatment than those before treatment in both groups(P ＜0.01),but the rosuvastatin group decreased even more significantly (P ＜ 0.05).The serum levels of high-density lipoprotein cholesterol(HDL-C) were higher in both groups after 12-week treatment,but the difference was not significant(P ＞ 0.05).The serum level of HDL-C in the rosuvastatin group tended to increase comparing with the simvastatin group after 12-week treatment(P ＞ 0.05).Statistical differences of liver and kidney function and serum CK were not found in both groups before and after treatment.The adverse reactions in the rosuvastatin group were few.Conclusions Rosuvastatin can not only significantly regulate blood lipids,but also reduce serum UA and hs-CRP,its security is good,so it can benefit HUA patients complicated with CHD in coastal areas. Key words: Rosuvastatin ; Hyperuricemia ; Coronary atherosclerotic heart disease ; Uric acid ; High sensitive C-reactive protein; Blood lipids
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call